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Hypofractionation trials and radiobiology of prostate cancer
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Evidence has accumulated suggesting that prostate 
cancer (PCa) may be particularly sensitive to radiation 
fraction size [1].  This has considerable implications for 
the delivery of radical radiation treatments suggesting that 
shorter treatments using higher dose/fraction schedules 
might improve the therapeutic ratio and make treatment 
more convenient for patients as well as using radiotherapy 
resource more effectively.  The fraction sensitivity of 
cancer and normal tissues is usually described by a linear 
quadratic equation.  The ratio α/β of the linear (α) and 
quadratic (β) terms is a useful measure of the “curviness” 
of dose effect curves.  Early responding tissues and many 
cancers typically have a high α/β ratio, making them 
sensitive to total dose but with a small fractionation 
effect.  Late responding tissues and perhaps PCa have 
a low α/β ratio, demonstrating increased cell survival at 
low dose/fraction and significantly greater toxicity/effect 
at high dose/fraction.  Four large randomised controlled 
trials testing modest hypofractionation for localised PCa 
have reported efficacy and side effect outcomes within the 
last year [2-5].  The largest trial, CHHiP, which included 
3216 patients [2] compared standard fractionation (SFRT) 
using 2.0Gy daily fractions (f) (total dose 74Gy) with two 
experimental hypofractionated (HFRT) schedules using 
3.0Gy/f (total doses of 60Gy and 57Gy).  The trial used 
a non-inferiority design and demonstrated that HFRT 
at 60 Gy was non–inferior to SFRT.  Five year disease 
control rates defined by biochemical (PSA)/clinical 
failure free outcome were for HFRT (60Gy) 90.6% (95% 
confidence intervals 88.5 - 92.3) compared with SFRT 
88.3% (86.0 - 90.2) (hazard ratio 0.84, (95% CI: 0.65 – 
1.07)); treatment related toxicities were low and similar. 
A complementary study design was used in the PROFIT 
trial [3] which included 1206 patients and compared SFRT 
using 2.0Gy/f (total dose 78Gy) with the same HFRT 
schedule of 3.0Gy/f (total dose 60Gy).  HFRT was again 
shown to be non-inferior to SFRT with identical 21% 
biochemical/clinical failure rates at 5 years.  In PROFIT 
gastro-intestinal side effects were increased in the SFRT 
group compared with HFRT group probably due to the 
higher SFRT dose given compared with CHHiP.  Both 
investigator groups suggested that HFRT (60Gy/20f in 
4 weeks) could be considered a new standard of care 
[6].  In contradistinction authors of the HYPRO study 
[4] came to different conclusions testing dose escalated 
HFRT.  804 patients received either SFRT 78Gy in 2Gy 
daily fractions or HFRT giving 64Gy in 3·4Gy fractions 
but importantly treating with three fractions per week and 
therefore protracting overall treatment time (OTT).  The 
gain in tumour control was smaller than might have been 
expected from the radiobiological model (HFRT 80.5% 
vs. CFRT 77.1%) and not statistically significant. The 
relatively unfavourable side effect profiles may be due 
to the higher HFRT doses delivered.  The trial failed to 
demonstrate either superior efficacy or non-inferior side 
effects for HFRT.  These 3 studies were undertaken in 
predominantly intermediate and high risk localised PCa. 
1092 men were included in RTOG trial 0415 [5] which 
tested the non-inferiority of HFRT in low risk PCa.  Daily 
schedules of SFRT (73.8Gy/1.8Gyf) were compared with 
HFRT (70Gy/2.5Gyf).  The cumulative incidence of 
biochemical recurrence at 5 years was 8% and 6% in SFRT 
and HFRT groups respectively which met the protocol-
specified non-inferiority criterion but late gastrointestinal 
and genitourinary side effects were increased with HFRT. 
There was no certain improvement in the therapeutic ratio. 
Together the 4 trials provide a rich source of data 
to further explore the radiobiology of prostate cancer 
response and hint that there may be a time factor resulting 
from tumour repopulation [1].  Independent estimation 
of the α/β value can be derived for each of the 4 trials 
by adjusting for the small differences in outcomes in the 
SFRT and HFRT trial groups.  In this case the estimates of 
α/β are 1.3Gy (PROFIT), 1.7Gy (CHHiP 57Gy) and 1.9Gy 
(CHHiP 60Gy) and the considerably higher values of 3.5 
Gy (HYPRO) and 6.9Gy (RTOG-0415).  Repopulation 
can be modelled using OTT and Tk - the number of days 
from the start of treatment when repopulation is assumed 
to begin.   A comprehensive approach to estimating these 
unknown variables is currently being developed [7]. 
However preliminary results assuming a proliferation rate 
(pr) of 0.31Gy [1] indicate that including a “time factor” 
improves the data fit.  Estimates of the α/β ratio increase 
and cluster between 3.8-5.4 Gy except for RTOG-0415 
which is an outlier at 31.5Gy. We speculate that this may 
be because of the low proliferation rate of low grade PCa. 
All these estimates are associated with wide confidence 
intervals and should be treated with considerable caution 
since  although they are derived from large clinical trial 
cohorts, it is not possible to resolve 3 unknown variables 
(α/β, Tk, pr) which may vary between the PCa risk groups 
included in these data.  Although the clinical trial results 
are  adequately robust to recommend a change in prostate 
cancer fractionation to 60Gy in 20 fractions much remains 
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to be learnt about PCa radiobiology which will have 
significant impact on the development of more extreme 
hypofractionation schedules [8].
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